 |
 |
SHANGHAI, Feb. 25, 2016 /PRNewswire/ -- CPhI China, hosted by UBM EMEA and China Chamber of Commerce of Medicines & Health Products Importers & Exporters and co-organized by UBM Sinoexpo, will be held on June 21-23, 2016 in Shanghai New International Expo Center. After fifteen years of experience and accumulation, CPhI China 2016 is poised for a larger size of exhibition, more elaborate zoning division and richer conferences and activities which combine to form an unprecedented annual event in China's pharmaceutical industry.
Continued rising momentum in BPC exports
In the first three quarters of 2015, the gross amount of import and export of western medicine slowed down, growing as little as 2.19% YoY. However, the rigid demand in export remained unchanged. Data showed that the demand for western medicine in North America, Europe, Asia and other major export markets continued increasing steadily and Chinese BPC export accounted for as high as 81.6%. Therefore, China has kept its position as the largest BPC supplier.
Additionally, the State Council had deployed policies and measures to boost foreign trade growth in July 2015, supplying a system support for the sustainable growth in China's drug import and export. Under these circumstances, CPhI China is expected to continue to give full play to its export oriented advantages and build a global one-stop pharmaceutical trading platform.
Well-developed product zoning and potential industrial development
Located in Shanghai New International Expo Center, CPhI China 2016 is expected to cover over 200,000m2 of the area and attract over 65,000 visitors from both, China and abroad. The show provides end-to-end scope experience, including pharmaceutical ingredients, pharmaceutical excipients & dosages, contracting, biotechnology, natural extracts, intermediates, and industry of fine chemicals.
The most anticipated zone in 2016 will be Excipient & Dosage, a popular sector for the modern pharmaceutical industry. Accounting for over 80% of a drug in its content, the quality of a pharmaceutical excipient determines the risks of drug safety and plays a key role in the quality of dosages.
The Excipient & Dosage zone, one of CPhI China's main draws, has been well-established after two years of growth. So far, the zone has converged North China Pharmaceutical, Huahai Pharmaceutical, Qilu Pharmaceutical, CSPC, Hisoar Pharmaceutical, Shijiazhuang No.4 Pharmaceutical, Livzon Pharmaceutical, Sunhere Pharmaceutical, NKY Pharmaceutical, ER-KANG Pharmaceutical, Xinhua Pharmaceutical and other domestically well-known excipient and dosage makers.
Rich onsite conference program and forums covering the latest trends
A series of high-quality conferences and forums will take place during CPhI China, bringing the latest market news for exhibitors and visitors, as well as establishing the platform for mutual study, dialogue, communication and rendering perfect chances for industry peers to build abundant interpersonal links.
The well-established forums under the CPhI China brand include the Seventh China-World CEO Summit, CPhI, ICSE & P-MEC China Innovation & Development Forum and CPhI International Agencies Updates, that will focus on methods to tackle fluctuating global pharmaceutical patterns and analyze relevant problems of things such as supervision and policy in pharmaceutical transformation and upgrading, committed to helping pharmaceutical companies further enhance their competitiveness.
Exhibiting Profile
Online visitor registration is now open. For more information please visit http://www.cphi.com/china to register or contact:
Ms. Tina Zheng
+86-21-64371178
tina.zheng@ubmsinoexpo.com
Logo - http://photos.prnasia.com/prnh/20160223/8521601135LOGO
Logo - http://photos.prnasia.com/prnh/20150730/8521504987LOGO
